Novocure Inc., of St. Helier, Jersey, just brought in another U.S. FDA approval for its tumor treating fields (TTF) devices, this time for the treatment of mesothelioma, with the NovoTTF 100L. The company now faces coverage and reimbursement hurdles before it has full access to the U.S. market for this new indication, although analysts are bullish the company eventually will bring the Centers for Medicare & Medicaid Services (CMS) on board.